Clinical trials: Paclitaxel, completed
Esophageal Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, carboplatin, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00281788
- Testing
- capecitabine, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Duke University
Esophageal Cancer
CCRT With Twice Weekly Paclitaxel and Cisplatin Followed by Surgery for Locally Advanced Esophageal Cancer
CCRT with twice weekly paclitaxel and cisplatin in patient with locally advanced esophageal cancer.
- Trial name
- NCT00154804
- Testing
- Paclitaxel, Cisplatin,Surgery, CCRT
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer
Randomized phase III trial to compare the effectiveness of surgery with or without combination chemotherapy in treating patients who have stage I non-small cell lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer
- Trial name
- NCT00002852
- Testing
- paclitaxel, carboplatin, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Pancreatic Cancer
A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer
The objective of study IOA-289-102 is to evaluate the safety and tolerability of escalating doses of IOA-289 in patients with metastatic pancreatic cancer in combination with standard chemotherapy consisting of gemcitabine and…
- Trial name
- NCT05586516
- Testing
- IOA-289
- Where
- 3 sites in Italy, United Kingdom
- Volunteers
- 16 people
- Sponsor
- iOnctura
Breast Cancer
Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer
The purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent breast cancer
- Trial name
- NCT01023204
- Testing
- Paclitaxel
- Volunteers
- 68 people
- Sponsor
- Bristol-Myers Squibb
Cervical Cancer
A Safety and Efficacy of CCRT With Paclitaxel/Carboplatin as Adjuvant Therapy to Post-operative Cervical Cancer Patients
The purpose of this study is to determine whether post-operative concurrent chemoradiation with paclitaxel/carboplatin is effective and safe in the treatment of high risk cervical cancer patients.
- Trial name
- NCT00340184
- Testing
- paclitaxel, carboplatin
- Where
- South Korea
- Volunteers
- 55 people
- Sponsor
- Korean Gynecologic Oncology Group
Melanoma
A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma
This Phase II, multicenter, randomized, double-blind, placebo-controlled trial was designed to estimate the efficacy and characterize the safety of bevacizumab when combined with carboplatin + paclitaxel chemotherapy compared…
- Trial name
- BEAM (NCT00434252)
- Testing
- bevacizumab, carboplatin, paclitaxel
- Volunteers
- 214 people
- Sponsor
- Genentech, Inc.
Breast Cancer
A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
To verify that combination therapy with trastuzumab + pertuzumab + eribulin brings similar PFS and better QOL compared to trastuzumab + pertuzumab + taxane in advanced/recurrent HER2-positive breast cancer patients who have no…
- Trial name
- NCT03264547
- Testing
- Pertuzumab, Trastuzumab, Docetaxel
- Where
- 2 sites in Japan
- Volunteers
- 446 people
- Sponsor
- Japan Breast Cancer Research Group
Triple Negative Breast Cancer
The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC
The purpose of this study is to evaluate the efficacy and safety of Sintilimab plus anlotinib combined with chemotherapy as neoadjuvant therapy in participants who have triple negative breast cancer (TNBC).
- Trial name
- NeoSACT (NCT04877821)
- Testing
- Sintilimab, Anlotinib, Nab paclitaxel
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Guangdong Provincial People's Hospital
Non-small Cell Lung Cancer
Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
The subjects who take part in this clinical research study have advanced non-small cell lung cancer (NSCLC) that has been previously treated with other drugs.
- Trial name
- NCT02730247
- Testing
- ramucirumab, nab-paclitaxel
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Liza Villaruz, MD
Non-Small Cell Lung Cancer, Brain Neoplasms
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)
This was an open-label, multicenter, single-arm, Phase II trial of bevacizumab combined with first- or second-line therapy in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with previously treated…
- Trial name
- NCT00312728
- Testing
- bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents
- Volunteers
- 115 people
- Sponsor
- Genentech, Inc.
Resectable Cholangiocarcinoma, Stage IB Intrahepatic Cholangiocarcinoma AJCC v8
Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
This phase II trial studies how well gemcitabine, cisplatin, and nab-paclitaxel work before surgery in treating participants with high-risk bile duct cancer in the liver (intrahepatic cholangiocarcinoma).
- Conditions
- Resectable Cholangiocarcinoma, Stage IB Intrahepatic Cholangiocarcinoma AJCC v8, Stage II Intrahepatic Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT03579771
- Testing
- Cisplatin, Gemcitabine, Nab-paclitaxel
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Emory University
Breast Neoplasms
A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer
The combination of docetaxel and gemcitabine has shown significant activity in patients with metastatic breast cancer. Several studies have activity in patients of multiple lines of therapy, including patients that have been…
- Trial name
- NCT00191672
- Testing
- Gemcitabine, Paclitaxel, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Metastatic Breast Cancer
Polymorphism Interaction to Predict Bevacizumab Efficacy
Although many attempts have been done to identify vascular endothelial growth factor-A (VEGF-A) single nucleotide polymorphisms (SNPs) correlated with bevacizumab response, in advanced cancer patients, the results are still…
- Trial name
- BEVAGENE (NCT01935102)
- Where
- Italy
- Volunteers
- 169 people
- Sponsor
- University of Pisa
Breast Cancer
An Observational Study of Avastin (Bevacizumab) in Combination With Paclitaxel in First-Line Treatment in Patients With HER2-Negative Metastatic Breast Cancer
This prospective observational study will evaluate the use in clinical practice, efficacy and safety of Avastin (bevacizumab) in combination with paclitaxel in first line in patients with HER2-negative metastatic breast cancer.
- Trial name
- NCT01661153
- Where
- 2 sites in Croatia
- Volunteers
- 16 people
- Sponsor
- Hoffmann-La Roche
In-stent Coronary Artery Restenosis
Paclitaxel Releasing Balloon in Patients Presenting With In-Stent Restenosis
The primary objective of this study is to evaluate the safety and efficacy of the paclitaxel releasing balloon in patients with in-stent restenosis in a coronary artery.
- Trial name
- PEPPER (NCT00961181)
- Testing
- Paclitaxel Releasing Balloon
- Where
- Germany
- Volunteers
- 81 people
- Sponsor
- Biotronik AG
Coronary Stenosis
PEPCAD I. The Paclitaxel-Eluting PTCA-Balloon Catheter to Treat Small Vessel
The objective of this study is to assess the safety and efficacy of the Paclitaxel-eluting PTCA-balloon catheter (3µg/mm2 balloon surface area) in the treatment of significant (≥ 70% and < 100 %) stenoses in native coronary…
- Trial name
- NCT00404144
- Testing
- Drug Eluting Balloon
- Where
- 9 sites in Germany
- Volunteers
- 120 people
- Sponsor
- Heart Centre Rotenburg
Laryngeal Neoplasms, Hypopharyngeal Neoplasms
Organ Preservation: Weekly Carboplatin & Taxol w/Concurrent RT for Locally Advanced Laryngeal & Hypopharyngeal CA
Organ Preservation: Weekly Carboplatin \& Taxol w/concurrent RT for locally advanced laryngeal \& Hypopharyngeal CA
- Trial name
- NCT00534729
- Testing
- Weekly Carboplatin & Taxol w/concurrent RT
- Where
- Saudi Arabia
- Volunteers
- 200 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Carcinoma, Non-Small Cell Lung Cancer (NSCLC)
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
The purpose of the study is to determine if nab-paclitaxel and carboplatin chemotherapy plus necitumumab is effective and safe in participants with stage IV squamous non-small cell lung cancer.
- Trial name
- NCT02392507
- Testing
- Necitumumab, Nab-Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Eli Lilly and Company
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma
Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy
For recurrent or persistent advanced cervical cancer patients, the first-line chemotherapy was based on platinum. However, if they were refractory to platinum-based chemotherapy, there were no other more effective medications or…
- Conditions
- Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemotherapy, Anti-PD-1 Antibody
- Trial name
- NCT04188860
- Testing
- A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Lei Li
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.